{
  "Cancer Histology Subtype (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        791, 
        797
      ]
    }
  ], 
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        798, 
        807
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        929, 
        952
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1010, 
        1030
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        676, 
        703
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        716, 
        721
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        592, 
        618
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        782, 
        790
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        708, 
        714
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        723, 
        736
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        705, 
        706
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PATHLAB_LIS|HOSPITAL 4^9999^MOH|PIMS|CCO|20160504000319|3D954690D0B41615E21B31B25BACEC86E49E72F8|ORU^R01|1605040003415537|P|2.5|||\nPID|1||9999999^^^^CMR^HOSPITAL 4&9999&MOH~9999999^^^^MRN^HOSPITAL 4&9999&MOH~9999999999&GK&^^^^JHN||XXXXXXX^XXXXX^^^^||99999999|F|^^^^^||999 XXXXXXX XXXXXX XXXX 999^^XXXXXXXXX^^X9X9X9^999||9999999999||||||||^^|||||||||N|||\nOBR|1|S16-6306|S16-7120|11529-5^Surgical Pathology Study Report^LN^P^Pathology^L|||201604200000|||||||201604201542|PAT&&CONSULT, SLIDES ONLY - HOSPITAL HOSPITAL (S16-6306)|||||N||201605040940||SUR|F|||||||^XXXXXXXXX^XXXX|\n\n\n\n\n\n\n\nPath report.site of origin\n\n1.CONSULT, SLIDES ONLY - HOSPITAL HOSPITAL (S16-6306)\n\n\nPath report.final diagnosis\n\n1. Breast (right, 10:00 o'clock mass), biopsy, HOSPITAL hospital S16-6306:\n- Invasive ductal carcinoma \n- Estrogen receptor positive (80%, moderate), progesterone receptor positive (80%, strong) and HER2 is positive (3+)\n\n\n\nPath report.relevant Hx\n\nAs per the referring institution's pathology report.\n\n\n\nPath report.comments\n\nReceived for review is material from right breast 10:00 o'clock mass core biopsy, procedure date is 22/03/2016.\nSections examined show cores of breast tissue infiltrated by nests of invasive carcinoma. The invasive carcinoma show no tubule formation, marked nuclear pleomorphism and frequent mitotic figures (Nottingham grade III/III in this limited biopsy).\nThe invasive carcinoma is estrogen receptor positive (80%, moderate), progesterone receptor positive (80%, strong) and HER2 is (3+) positive. \n\n\n\n"
}